HuidaGene Therapeutics and Synthego Announce Licensing Partnership for China-Developed Gene Editing Tool hfCas12Max®
Synthego
Gene Engineering Solutions Provider
In recent years, the gene editing field has flourished, and China's original gene editing companies have gradually appeared on the world stage. As a pioneer in the gene editing field, Hui-Gene Therapeutics successfully achieved its first overseas expansion, indicating that China's original gene editing technology has gained international recognition.
Shanghai, China, Redwood City, California, USA, May 29, 2024 — Hui-Gene Therapeutics and Synthego jointly announced,Both parties discussed the high-fidelity nuclease hfCas12Max®Reached a licensing cooperationHui-Gene Therapeutics is a global biotechnology company at the clinical stage, focusing on the development of CRISPR gene therapy drugs. Synthego is an industry leader providing innovative solutions for genetic engineering. This collaboration not only demonstrates Hui-Gene Therapeutics' hfCas12Max®The important clinical application potential also reflects Synthego's continued focus on advanced GMP manufacturing capabilities. According to the undisclosed financial terms of the licensing agreement, Hui-Gene Therapeutics will grant Synthego ownership of hfCas12Ma.x®The rights to produce and commercially sell nucleases, the rights to optimize gRNA for research use, and hfCas12Max®®Nuclease for sublicensing rights for therapeutic purposes.
This important collaboration will streamline the development process of CRISPR-based therapeutic applications, providing developers with high-precision, high-efficiency, and next-generation genomic editing tools to enhance the development efficiency of CRISPR therapies.Dr. Yao Xuan, Co-founder and President of Hui-Gene Therapeutics"Hui-Gene Therapeutics, as one of the global leaders in gene editing technology and therapy, possesses independently developed CRISPR gene editing technology and has deeply laid out its product portfolio in the neurological and ophthalmological fields. In the future, together with our partner Synthego, we will jointly promote research and new drug development in the CRISPR gene therapy field, accelerating the provision of transformative gene therapies to patients worldwide."
Synthego CEO Craig ChristiansonRegarding the enthusiasm for the collaboration with Hui-Gene Therapeutics' hfCas12Max: "The combination of our advanced CRISPR GMP manufacturing capabilities and regulatory expertise with Hui-Gene Therapeutics' next-generation nuclease technology is a crucial step in advancing transformative therapies in the cell and gene therapy field. This collaboration highlights Synthego's commitment to CRISPR therapeutics, as we focus on GMP manufacturing and comprehensive CRISPR solutions to support therapy development. This partnership will bring hfCas12Max..."®"Integrating into our CRISPR toolkit perfectly aligns with our original intention and aspiration to improve the accessibility and efficiency of gene-editing tools."
hfCas12Max®It is Hui-Gene Therapeutics relying on HG-PRECISE®Technical Platform, Independently Developed and Optimized New DNA Editing System: hfCas12Max®Demonstrates superior on-target editing efficiency and lower off-target activity in mammalian cells, with the size advantage of being deliverable by a single AAV package. hfCas12Max®The commercialization will significantly improve the accessibility of the CRISPR gene editing system, provide greater operational flexibility, and promote the development of CRISPR-based cell and gene therapies.
This collaboration solidifies the two companies' positions as catalysts for innovation, advancing their shared mission — to transform genomic medicine and achieve unprecedented therapeutic outcomes.
hfCas12Max®Collaboration is the first step for Hui-Gene Therapeutics to establish itself in China and go global. Prior to this collaboration, in August 2023, Hui-Gene Therapeutics had already partnered with Kactus Biosystems to accelerate the commercial application of this gene-editing tool enzyme in the Greater China region. Hui-Gene Therapeutics has been building up its strength over time, focusing on the development of gene-editing tools with fundamental innovative technologies, and possesses a series of gene-editing toolkits suitable for different scenarios, providing cell and gene therapy companies with more and better technical options.
About Hui-Gene Therapeutics
Hui-Gene Therapeutics Utilizes Its Proprietary HG-PRECISE®Platform to discover, design, and develop new CRISPR gene therapies. Clinical-stage programs currently being advanced by the company include HG004 for the treatment of RPE65 mutation-associated inherited retinal diseases.(Granted with both ODD and RPDD designations by the FDA)，HG202(RNA Editing Therapy)Treatment of Neovascular Age-Related Macular Degeneration（nAMD）, and preclinical gene editing pipeline, including HG204(RNA Editing Therapy)Treatment of MECP2 Duplication Syndrome（MDS）(Granted with both U.S. ODD and RPDD designations, and European ODD designation)、HG302(DNA Editing Therapy)Treatment of Duchenne Muscular Dystrophy (DMD)(Granted dual designation of ODD and RPDD), and HG303(DNA Editing Therapy)Treatment of Amyotrophic Lateral Sclerosis（ALS）Such projects. Hui-Gene Therapeutics has a rich and in-depth intellectual property portfolio layout and is becoming a leader in the field of neurology and ophthalmology gene therapy.
About Synthego
Synthego is a leading provider of genomic engineering solutions, offering a comprehensive suite of products and services to accelerate the development of CRISPR-based cell and gene therapies. Synthego is committed to supporting researchers and innovators, driving advancements from preclinical to clinical applications with its cutting-edge CRISPR technology and expertise.